Forschner, J., Huynh, J., Schroeder, C., Armeanu-Ebinger, S., Seibel-Kelemen, O., Gschwind, A., . . . Reitmajer, M. Adjuvant anti-PD-1 therapy improves melanoma-specific survival in stage IIIC-IV melanoma patients with high tumor mutation burden and BRAF V600 mutation. Frontiers Media S.A.
Chicago Style (17th ed.) CitationForschner, Julia, et al. Adjuvant Anti-PD-1 Therapy Improves Melanoma-specific Survival in Stage IIIC-IV Melanoma Patients with High Tumor Mutation Burden and BRAF V600 Mutation. Frontiers Media S.A.
MLA (9th ed.) CitationForschner, Julia, et al. Adjuvant Anti-PD-1 Therapy Improves Melanoma-specific Survival in Stage IIIC-IV Melanoma Patients with High Tumor Mutation Burden and BRAF V600 Mutation. Frontiers Media S.A.
Warning: These citations may not always be 100% accurate.